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Introduction
Retinoblastoma (RB) is the most common ocular cancer in 
children. Though the incidence of RB is low (15.3-42.5 per million 
children aged 0-4) it presents as a hereditary cancer in approximately 
50% of cases, thus, it is crucial to be diagnosed for its hereditary 
predisposition [1]. The development of RB is due to inactivation of 
the RB1 tumor suppressor gene in the developing retina (GenBank 
accession No L11910, MIM 180200). RB may be either bilateral 
(approximately 40%) or unilateral (60%) and in some rare instances 
it may present as a trilateral or quadrilateral tumor, including an 
intracranial primitive neuroectodermal tumor in the pineal or less 
frequently suprasellar region (5% of children with constitutional 
mutations) [2,3].  Hereditary RB is often associated with second, 
even multiple primary nonocular malignancies, with a cumulative 
incidence throughout the lifespan [4]. Sometimes, RB may occur in 
association with other syndromes, such as the 21 trisomy (Down) [5]. 
Bilateral RB is caused by a germline mutation in one RB1 allele, 
which may be inherited (10%) or arisen de novo, followed by a somatic 
mutation in the other allele. Unilateral RB is caused in most cases by 
two somatic mutations (approximately 80%) [6]. Mutations in both 
RB1 alleles result in a loss of function of the retinoblastoma protein, 
leading to deregulation of cell proliferation and tumor development. 
Individuals with germline mutations have hereditary 
predisposition to retinoblastoma, thus, the identification of the 
causative mutation is important to predict the risk for tumor 
development in family members. Retinoblastoma is a potentially 
curable cancer and may be diagnosed by several presenting signs 
such as leukocoria and strabismus, which correlate with a high 
survival rate of the patient. An early diagnosis is critical for survival 
and eye preservation in children who carry the mutation, which could 
be detected even by prenatal analysis. Moreover, a preimplantation 
test to select embryonic cells free of mutation, followed by in vitro 
fertilization may be employed to prevent the birth of children at 
risk. On the other hand, children not carrying the mutation can be 
excluded from the invasive ophthalmologic procedure to detect the 
tumor [7,8].  The most common treatment for RB in developing 
countries is enucleation, with or without an adjuvant chemotherapy 
according to tumor presentation [9,10,11]. 
Screening for RB1 mutations is challenging because of their 
heterogeneity, with over 900 mutations reported to date [12] and 
their distribution along the RB1 exons, the promoter region and 
the flanking intronic sequences. Moreover, only few mutations on 
specific sites are recurrent, such as the C>T transitions at the CpG 
dinucleotides, especially those affecting the arginine codon. Most 
of the mutations are unique or rarely reported [13,14]. Approaches 
using several techniques for mutation analysis may detect alterations 
in the RB1 gene in about 80 to 90% of patients [13,15,16]. The main 
barriers for achieving an efficient detection of RB1 mutations is the 
presence of mosaicism [17] and the location of mutation within non 
coding regions, far from the exon-intron junctions [18].  In addition, 
about half of the RB patients do not carry mutations in constitutional 
DNA but only in tumor DNA. Tumor tissue is not readily available; 
either because the patient was not enucleated, or was enucleated 
many years ago or otherwise the tumor sample is reserved in the bank 
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for other analyses. In the absence of tumor DNA the failure to detect 
mutations in constitutional DNA does not provide certainty about 
the non-heritable, somatic nature of the causative mutation, since 
there is still a little chance that the constitutional heritable mutation 
is located outside the analyzed regions.
Most of the RB1 mutations are nonsense or frameshift including 
whole RB1 gene deletions, interexonic deletions, small intraexonic 
frameshift deletions or insertions and splice site mutations. All 
these mutations result in the absence of retinoblastoma protein. 
Some of the RB1 mutations such as missense, in frame deletions or 
those located in the promoter region are less common. This type 
of mutations is associated with low penetrance, consisting in fewer 
tumors (unilateral RB) or even an absence of tumors. In this regard, it 
is noteworthy that some unilateral RB patients carry a low penetrant 
germline mutation [13,15,19]. 
In a previous study we reported the results of our experience in 
retinoblastoma testing throughout 20 years, using a methodology that 
has evolved over the study period [19]. Here we present the results 
of RB1 mutations in retinoblastoma patients with different clinical 
presentations, some of them with a rare multicentric retinoblastoma 
or with a second nonocular malignancy, as well as the rare association 
of RB with Down syndrome. A comprehensive approach, based on 
our previous experience, was used to identify the causative RB1 
mutations, including the novel ones, and to detect children with 
hereditary condition. These data are crucial to provide genetic 
counseling to the family.
Materials and Methods
Patients
Retinoblastoma patients were referred from the “Hospital de 
Pediatría JP Garrahan” (Buenos Aires, Argentina) as well as other 
pediatric health care centers in Argentina. The RB diagnosis was 
established by current ophthalmologic/histological criteria. A total 
of twenty retinoblastoma cases were studied, including fourteen 
sporadic unilateral, one of them associated with Down syndrome, 
three sporadic bilateral, one familial with two bilateral patients, 
one of them with a second tumor, and two sporadic multicentric. 
Informed consent for genetic analyses was signed by parents of the 
affected children.
DNA isolation and genotyping of polymorphic loci
Deoxyribonucleic acid (DNA) was obtained from peripheral 
blood leukocytes using the cetyltrimethylammonium bromide 
(CTAB) method and from frozen tumors by treatment with proteinase 
K, phenol/chloroform purification and ethanol precipitation. 
Segregation analysis of five polymorphic loci within the RB1 gene 
included two restriction fragment length polymorphisms (RFLPs: 
BamHI and XbaI, introns 1 and 17), and three microsatellites (Rbi2, 
Rbi4 and Rb1.20 introns 2,4 and 20), it was performed as previously 
described [19]. 
Mutation analysis 
The mutation screening was performed in blood DNA samples 
from all patients and in tumor DNA samples from the six patients 
with an available tumor biopsy. PCR-amplification and sequencing of 
the 27 exons and the promoter region of RB1 gene was performed as 
already described using an ABI 3130XL genetic analyzer [19].  All the 
mutations were confirmed by both direction sequencing from separate 
PCR reactions and by their absence in normal control individuals. 
Mutations were described according to the nomenclature [20] using 
the RB1 sequence from the GenBank, accession No L11910. The 
identified mutations were submitted to the Retinoblastoma Database 
2011 [14].
Multiplex Ligation-dependent Probe Amplification assay 
(MLPA) was performed using the Salsa MLPA kit PO47-B1 RB1 
(MRC Holland). Fluorescent in situ hybridization analysis (FISH) 
on metaphase spreads was performed using 13q14 (RB1) specific 
green probe (Qbiogene Molecular Cytogenetics, Irvine, CA, USA). 
Quantitative multiplex-PCR analysis of the 27 RB1 exons and the 
main body of the promoter was performed as described [13]. 
Cloning of PCR products in pGEM-T vector
The vector contains thymidine residue (T) in the 3´ends for its 
pairing with the (A) residue incorporated by Taq polymerase in 
the PCR products. This vector also includes a multiple cloning site 
in the region encoding for α peptide of ß galactosidase, inactivation 
of this gene by insertion of a PCR product allows the identification 
of the recombinant clones. Cloning was performed as described 
[21]. In brief, the PCR products are ligated to the vector pGEM-T 
and the mixture was transformed into DH5α competent bacteria 
growing in a media with an inducer of ß galactosidase (IPTG) and 
the chromogenic substrate 5-bromo-4chloro-3-indolyl-ß-galactoside 
(X-Gal). Recombinant vectors produced white colonies, while 
vectors without the insert originated blue colonies. The recombinant 
vector was extracted from white colonies and analyzed by digestion, 
electrophoresis and sequencing. 
Real-time quantitative PCR
Quantitative values were obtained from the threshold cycle 
number (Ct) at which the increase in the signal, associated with 
the exponential growth of PCR product, begins to be detected. The 
results, presented as N fold differences in target gene relative to 
Albumin gene (one copy gene) and termed N target, were determined 
as follows: N target=2ΔCt,  where the ΔCt value of the sample was 
determined by subtracting the average Ct value of the target gene 
from the average Ct value of the Albumin gene. For determination 
of the copy number of RB1 gene two exons were selected: the Exon 
11, which is mutated in one tumor DNA, and the wild type Exon 24, 
using a forward primer for Exon 11 that only recognized the mutated 
sequence, 5´ TAATTCCTCCACACAGAGS 3´.
The reverse primer for Exon 11 and the primers for Exon 24 
were the same as those used for sequencing, the primers for albumin 
gene were: Fw 5’ TGAAACATACGTTCCCAAAGAGTTT 3’ 
Rev 5’ CTCTCCTTCTCAGAAAGTGTGCATAT 3’. Tumor and 
constitutional DNA (leukocyte DNA) of the patient were assayed 
using the DNA from a pool of 6 normal individuals as normal 
reference. The quantitative PCR was performed in a total volume of 
25 μl containing 12.5 μl of SYBR Premix (Bio-Rad), 2 μl of genomic 
DNA from each of the four serial dilutions containing 60 ng, 30 ng, 
15 ng and 7.5 ng of DNA, and 5 μl of primers (5 μM each), with two 
replicates per sample. The serial dilutions were performed to test if 
the efficiency of all reactions were comparable in order to use the 
quantitative method. Reaction run with the following conditions in 
an ABI 7900HT (Applied Biosystems, Foster City, CA, USA): 95°C 
for 10 min and 40 cycles of 95°C 10 s/60°C 15 s/72°C 20 s.
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RNA analysis
Total RNA was extracted from blood leukocytes of the patient 
and a control individual using the TRIzol reagent (Invitrogen) and 
following the manufacturer´s protocol. Prior to RNA extraction, 
leukocytes were treated with 200 μg/ml of puromycin (Sigma-
Aldrich, Inc. Saint Louis, USA) for 4hr at 37 ºC in order to prevent 
the degradation of mutant transcripts [18]. First strand of cDNA 
was synthesized with a mixture of random hexamers and the reverse 
transcriptase Superscript II (Invitrogen). A total of 2 μl of the cDNA 
reaction mixture where amplified in four overlapping fragments 
using PCR primers designed to obtain full coverage of the RB1 cDNA 
coding region [18]. PCR products were purified and subjected to 
sequencing.
Results
Clinical data, treatment and outcome
Most of the patients presented a unilateral RB (70%), and the 
tumor biopsy was available from six of them. The remaining showed 
different clinical presentations, bilateral, trilateral and quadrilateral 
RB, one RB patient with a second tumor and one RB associated 
with Down syndrome.  The patient with a trilateral retinoblastoma 
included a neuroectodermal pineal tumor while another patient 
developed a suprasellar and also a small pineal tumor in addition to 
RB, thus he was considered as a quadrilateral retinoblastoma [22]. 
This patient died at seven months as a result of multiple brain 
metastases, despite an aggressive clinical treatment. The patient with a 
rare presentation of two syndromes, 21 trisomy (Down) and unilateral 
retinoblastoma had poor health and suffered a relapse. Thirteen of the 
RB patients were enucleated and eight of these received additional 
chemotherapy. The remaining, including those with multicentric 
retinoblastoma and the younger sibling of the familial case, were not 
enucleated and received chemotherapy and/or radiotherapy. The eye 
outcome of the patients and the causative mutations are displayed in 
Table 1.
RB1 mutations
Six germline and seven somatic mutations were found in eleven 
patients, these included three nonsense, three frameshift, two splice 
site mutations and five gross RB1 rearrangements. 
Germline mutations were heterozygous (mutations that are 
present at a level of approximately 50% of the leukocyte DNA), while 
somatic mutations, identified in tumor DNA, were both homozygous 
or hemizygous (three) and heterozygous (four).
Nonsense and frameshift mutations
Nonsense germline mutations were identified in two sporadic 
patients: one bilateral (#565) - diagnosed at seven months - and the 
other unilateral (#600) - diagnosed at 30 months. Both were treated 
by enucleation followed by chemotherapy. A nonsense somatic 
mutation was identified in a tumor of one sporadic unilateral patient 
(#656), who was diagnosed and enucleated at 25 months without 
any other treatment. The second mutation in this tumor was the loss 
of heterozygosity (LOH). These three nonsense mutations were the 
well-known recurrent C>T transitions, one at CGA codon of exon 
10, the other at CAA codon of exon 18 and the third at CGA codon 
of exon 23 respectively. 
Two frame shift germline mutations-CC and TA-2bp deletions-
were identified in exon 18 and exon 22 from a trilateral and a 
quadrilateral patient respectively. Both were considered novel 
mutations as they had not been reported in the RB1 gene mutation 
database [11]. The trilateral patient (#582), presenting bilateral RB and 
a pineal tumor, was diagnosed at 10 days and received chemotherapy 
according to the COG scheme (children oncology group). At present 
she is 3 years old and clinically stable. The quadrilateral patient (#568) 
had a rare presentation with a huge suprasellar mass, massive bone 
marrow and skull metastases and, in addition, a small pineal tumor. 
This patient was diagnosed at one month and received chemotherapy 
according to the COG scheme; however, he died at seven months.
Splice mutations 
The same recurrent splice mutation-a G to A transition at the 
conserved donor site of intron 12-was identified in tumor DNA 
of two unilateral patients. One of them diagnosed at 17 months 
and enucleated without any other treatment (#551), and the other 
diagnosed at 16 months and treated by enucleation and chemotherapy 
(#621). This mutation was absent from constitutional DNA of both 
patients The second mutation identified in these tumors was a LOH 
in one of the patients (#551) and an insertion in exon 11 in the other 
patient (#621), which is described in the next section.
Gross rearrangements
The gross rearrangements were identified in five patients and 
comprised either deletions or duplications, ranging from two 
exons to a whole RB1 gene, including neighboring centromeric and 
telomeric genes. A deletion of two exons (22 and 23) was identified 
in the constitutional DNA of a bilateral patient (#570), diagnosed at 
6 months and treated by irradiation. Her current age is 17 years and 
she preserved her vision. A second grade RB cousin of this patient did 
not carry this mutation and no other mutations were detected in his 
blood DNA. As this was a unilateral patient the causative mutation 
probably occurred in the tumor. Thus, both cousins developed RB as 
a result of different mutations.
Whole RB1 gene deletions were found in two patients, one in 
the constitutional DNA from a child who presented tumors in both 
eyes at the early age of 15 days, and the second, in the tumor DNA 
from a patient with retinoblastoma associated with Down syndrome. 
This deletion was heterozygous in tumor DNA (the second mutation 
was not identified) and it was absent from constitutional DNA. 
The patient with the two syndromes was diagnosed for RB at 20 
months and enucleated, however, he suffered a relapse and received 
chemotherapeutic treatment, finally, and he died due to poor health.
Two different duplications were identified in tumor DNA from 
one patient (#621): 1) in tandem duplication of a 56 bp sequence in 
exon 11; and 2) duplication of the whole RB1 gene plus the flanking 
centromeric and telomeric genes. The 56 bp duplication was validated 
by cloning of the exon 11 PCR product in pGEM-T vector. Four white 
colonies were obtained, two of them contained the wild type exon 
11 and the other two the mutant exon 11. These data confirmed the 
presence of a heterozygous 56bp insertion in exon 11. The duplication 
of the whole gene was validated by Real-Time PCR analysis of two 
RB1 exons, one carrying the mutation (exon 11) and the other with a 
wild type sequence (exon 24). 
This analysis revealed the presence of three alleles of exon 24 and 
two alleles of the mutant exon 11 as compared with the albumin gene 
(two alleles). Therefore, there were three copies of RB1 gene in the 
tumor, two with an insertion of 56 bp in exon 11 and one with a wild 
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type exon 11. In addition to these duplications a third mutation was 
identified in the same tumor, the splice site G to A substitution in 
intron 12, aforementioned in the section “Splice Mutations”. Thus, 
the third copy of RB1 gene, with a wild type exon 11 presumably 
carried the splice site mutation in intron 12. All three mutations were 
heterozygous and were absent from constitutional DNA.
Duplication of two exons, 3 and 4, was identified in the tumor 
DNA of a unilateral patient (#554) diagnosed at 29 months and treated 
by enucleation and chemotherapy. This was a somatic mutation as 
it was absent from constitutional DNA, the second mutation in this 
tumor was a LOH. 
Familial RB case
One family included two bilateral RB siblings, one 
asymptomatic sibling and asymptomatic parents. The older 
RB patient was diagnosed at 18 months of age and was treated 
by enucleation, chemotherapy and radiotherapy. At the age 
of 18 years he also developed an osteosarcoma and received 
chemotherapeutic treatment. 
His younger sister was diagnosed at an earlier stage and treated 
solely with focal therapy (laser coagulation). Molecular testing by 
sequencing, MLPA, FISH and QM-PCR analyses at the DNA level was 
uninformative for the causative mutation. Analysis at RNA level, in 
conditions that inhibit the surveillance pathway of nonsense mediated 
decay, showed a double peak chromatogram with superimposed 
sequences of exons 8 and 9. These results indicate an absence of 
exon 8 in one RB1 copy, which would result in frameshifting and 
generation of a stop codon. 
However, the control DNA (normal individual) treated with 
puromycin also showed a heterozygous absence of exon 8 in the 
blood sample, therefore this anomaly would not be the causative 
mutation and the lack of exon 8 might result from an alternatively 
spliced transcript [23]. Segregation analysis of five polymorphic loci 
within the RB1 gene revealed the haplotype-at-risk, shared by the two 
RB siblings, the asymptomatic sibling and the asymptomatic father 
(Figure 1).
Discussion
Different RB presentations and outcome
Molecular genetic testing of RB patients identifies children 
with a heritable condition (approximately 50%) who have a genetic 
predisposition for second tumors. Moreover, the children with 
unilateral hereditary RB are at risk of bilateralization (metachronous 
bilateral RB) [24]. Molecular analysis of patient`s relatives detects 
presymptomatic RB children, allowing early diagnosis and treatment. 
For these reasons, the identification of mutations is essential for 
planning treatment strategies and a long-term follow up, in order 
to improve survival rates and the life quality of patients and their 
relatives [8]. On the other hand, the search for mutations among the 
family members detects the non-carriers of RB mutations, reducing 
in this way the clinical screening procedures, which have potential 
morbidity for these children.
The high survival rate (90-95%) in developed countries contrasts 
with poor prognosis for RB in developing countries, where the vast 
majority of RB patients live [25]. In our country a mean of 44 new 
RB patients are treated yearly at the Garrahan Hospital (reference 
RB center), but probably there are still more children with RB, living 
in poverty and without receiving medical attention. At present, the 
survival rate of the ascertained patients is about 80%, with the follow-
up continuing into adulthood. The average age at diagnosis, according 
to uni, bi or trilaterality of the tumor, is similar to that reported in 
other countries [26]. 
Trilateral patients represent 3.7% of the children with germline 
RB1 mutations in our cohort of RB patients (three in a total of 81 
patients with bilateral/familial RB), in full agreement with previously 
reported data [2]. Two of these RB patients had had a pineal tumor and 
the third had developed a suprasellar tumor and later a small pineal 
one. The suprasellar malignancy was presented as very aggressive and 
at an early age, causing a prompt death in spite of intensive treatment. 
The two patients with pineal tumor were less severely affected, one of 
them, reported previously [19] died at the age of four years and the 
other is still alive at the age of three years. A patient, who had had a 
bilateral/familial RB (#559), later developed a second primary tumor, 
an osteosarcoma. This fact along with our previous results on second 
malignancies in another patient with familial RB ( #112) [19] support 
the findings that patients with familial RB have a slightly higher risk 
of developing second tumors [27]. One patient was a rare case with 
two different syndromes, Down and retinoblastoma. Previous reports 
have suggested an increased incidence of leukemia and some solid 
tumors like retinoblastoma in Down patients [28,29]. A possible 
mechanism of tumor development may be related to gene dosage on 
chromosome 21 [28]. 
Genotype and Phenotype  
Germline mutations were identified in five of the six patients with 
bilateral/familial RB and in one of the fourteen unilateral patients. 
Additionally, somatic mutations were found in tumor DNA from 
five unilateral patients. All functional classes of mutations were 
identified and they were distributed throughout the RB1 gene, but 
predominantly in the 3´ region. Nonsense/frameshift mutations, 
which have been reported to be the most common RB1 mutations, 
were found in six patients (46%), gross rearrangements were identified 
in five patients (39%) and the splice site mutation was observed in two 
patients (15%). Three out of the four nonsense/frameshift mutations 
of germline origin were associated with severe phenotype: a bilateral 
Figure 1: Pedigree and haplotype analysis of one family with two RB siblings. 
The polymorphisms analyzed are indicated at the left of the pedigree. The 
haplotype at risk is indicated in bold. 
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RB (nonsense mutation), a trilateral RB and a quadrilateral RB 
(frameshift 2bp deletions in each one). Of note, one trilateral case, 
previously reported, was also caused by a frameshift 1bp deletion 
[19]. Thus, the multicentric RB cases were associated with frameshift 
intraexonic deletions in our group of RB patients. Unexpectedly, one 
nonsense germline mutation was associated with a unilateral RB of 
late diagnosis and an advanced development of tumor that had to be 
enucleated. These data will be significant for genetic counseling.
One of the gross rearrangements, the duplication of exons 3 
and 4 found in tumor DNA, is similar to that previously reported in 
constitutional DNA of an RB patient, duplication of exons 3 and 4 
in tandem orientation, resulting in frameshifting and generation of a 
stop codon [18].  The appearance of the same uncommon mutation in 
different tissues, germ cells and retinoblasts, suggest that it may occur 
by a similar mechanism in both tissues, namely duplication in tandem 
orientation, leading to premature termination of translation. The other 
gross rearrangement, a germline deletion of exons 22-23, presumably 
had the same consequence as the above mentioned, frameshifting and 
a premature stop codon. It is remarkable that one germinal whole 
RB1 gene deletion was detected in a bilateral RB patient soon after 
birth. Our previous results as well as other reports show that the 
whole RB1 gene deletions and cytogenetic deletions occur mostly in 
unilateral patients [19,30]. The donor splice-site mutation in intron 
12, identified in two of our patients, is the most common splice-site 
mutation in RB patients, which leads to exon 12 skipping generating 
a stop codon [18]. The presence of three mutations in the RB1 gene 
of one tumor DNA is an uncommon event. In addition, two of them 
were rare mutations, the 56bp duplication in exon 11 was novel, and 
the duplication of the whole gene was reported in tumor DNA of two 
patients, but probably without functional inactivation of the RB1 
gene [31]. On the contrary, the presence of three mutations in one 
patient from our study allows us to hypothesize that the RB1 gene 
was inactivated by two mutations, an insertion of 56 bp in exon 11 
of one copy and a splice site mutation in intron 12 of the other copy, 
which led to development of the tumor. Later during the continuous 
proliferation of retinoblasts occurred another genetic alteration, a 
duplication of the RB1 copy with the mutated exon 11, since there 
were two copies of the mutant exon 11 and three copies of an RB1 
exon without mutation (exon 24).
Indirect analysis in familial RB
The polymorphic loci within the RB1 gene were useful in 
identifying the at-risk-haplotype in one familial RB case, where the 
direct DNA analysis was uninformative. These data allowed us to 
detect individuals likely of carrying the mutant RB1 allele but who do 
not show signs or symptoms of RB. In order to clarify what type of RB1 
mutation caused tumor development in the two affected siblings we 
analyzed the genetic and clinical data in this family. Previous findings 
show that RB patients with nonsense mutations are more susceptible 
to develop second non ocular tumor than RB patients with low 
penetrant mutations [32]. Thus, the fact that both affected siblings 
had had a bilateral RB and that the older one, in addition, developed 
an osteosarcoma, suggest that the causative RB1 mutation should be 
highly penetrant, leading to a functionally disabled protein. However, 
this assumption contrasts with the presence of at-risk-haplotype, and 
hence a mutant RB1 allele, in two unaffected members of the family, 
the father of RB siblings and their healthy brother. This discrepancy 
may be explained by the presence of mosaicism in the unaffected 
father, who could have transmitted the mutant chromosome to the 
affected offspring and the wild type chromosome, with the same 
haplotype, to the healthy son. Another possibility is the influence of 
genetic factors that can modify the expressivity of RB and therefore 
the genotype-phenotype outcome [33]. 
Mutations at RNA level
The absence of mutations in the DNA coding regions may indicate 
that the alteration occurred in other DNA locations, such as the deep 
intronic sequences, not reached in the amplified products of exons 
plus flanking intronic sequences [18,34]. Analysis at RNA level of the 
familial RB case showed an absence of exon 8 in the patient and also 
in a normal individual. These results are in line with previous findings 
in normal breast and prostate tissue that show a skipping of exon 8 
originating an alternative transcript in small amounts ~3% [23]. This 
transcript would be subjected to nonsense-mediated decay (NMD) 
and can only be detected by pretreatment of cells with puromycin. 
No other alterations at RNA level were identified until now. Since 
deep intronic mutations are a rare event, found in a small percentage 
of patients with undetectable DNA mutations [18], other genetic 
alterations should be investigated. The search for a causative RB1 
mutation in this family is being pursued at molecular and cellular 
levels.
Conclusions
This study allowed us to identify interesting and rare RB1 
mutations, as those found in one RB tumor with three mutations 
in the RB1 gene; this finding may be relevant to RB biology. 
Furthermore, several rare clinical presentations were observed: 
trilateral and even quadrilateral tumors, developed from precursor 
cells similar to retinoblasts in the pineal and suprasellar regions and 
retinoblastoma associated with Down syndrome. The identification 
of somatic mutations in five unilateral patients was useful to rule out 
hereditary RB predisposition. Segregation analysis of polymorphic 
loci enabled the identification of mutation carriers in one familial 
case without evidence of RB1 mutations. The data obtained in this 
study are crucial for genetic counseling of the affected families and 
support the relevance of performing complete genetic screening for 
RB1 mutations in both tumor and constitutional tissues. 
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